UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Tenax Therapeutics, Inc.

(Name of Issuer)

 

Common stock, $0.0001 par value per share

(Title of Class of Securities)

 

88032L605

(CUSIP Number)

 

August 8, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)
   
x Rule 13d-1(c)
   
¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 88032L605 Page 2 of 14

 

1.

Names of Reporting Persons

 

Venrock Healthcare Capital Partners III, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)    (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

PN

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants (as defined below) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of warrants (the “Common Warrants”) and/or pre-funded warrants (the “Pre-Funded Warrants” and, together with the Common Warrants, the “Warrants”) held by the Reporting Persons as a result of the Beneficial Ownership Blockers (as defined below). Each of the Common Warrants and the Pre-Funded Warrants contains a provision (the “Beneficial Ownership Blockers”) which precludes exercise of the Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 3 of 14

 

 

1.

Names of Reporting Persons

 

VHCP Co-Investment Holdings III, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)    (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

OO

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 4 of 14

 

1.

Names of Reporting Persons

 

Venrock Healthcare Capital Partners EG, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)    (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

PN

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 5 of 14

 

1.

Names of Reporting Persons

 

VHCP Management III, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)     (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

OO

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 6 of 14

 

1.

Names of Reporting Persons

 

VHCP Management EG, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)    (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

OO

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 7 of 14

 

1.

Names of Reporting Persons

 

Shah, Nimish

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)     (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

IN

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 8 of 14

 

1.

Names of Reporting Persons

 

Koh, Bong

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) x (1)     (b) ¨

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

355,224 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

355,224 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

355,224 (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

9.99% (3)

12.

Type of Reporting Person (See Instructions)

 

IN

 

(1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

 

(2)Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.

 

(3)This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

 

 

 

CUSIP No. 88032L605 Page 9 of 14

 

Item 1.
  (a)

Name of Issuer

 

Tenax Therapeutics, Inc.

 
  (b)

Address of Issuer’s Principal Executive Offices

 

101 Glen Lennox Drive, Suite 300

Chapel Hill, NC 27517

 
Item 2.
  (a)

Name of Person Filing

 

Venrock Healthcare Capital Partners III, L.P.

VHCP Co-Investment Holdings III, LLC

Venrock Healthcare Capital Partners EG, L.P.

VHCP Management III, LLC

VHCP Management EG, LLC

Nimish Shah

Bong Koh

 

  (b) Address of Principal Business Office or, if none, Residence

 

  New York Office: Palo Alto Office:
     
  7 Bryant Park 3340 Hillview Avenue
  23rd Floor Palo Alto, CA 94304
  New York, NY 10018

 

  (c)

Citizenship

 

All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

 
  (d)

Title of Class of Securities

 

Common Stock, $0.0001 par value

 
  (e)

CUSIP Number

 

88032L605

 
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable

 

 

 

 

CUSIP No. 88032L605 Page 10 of 14

 

Item 4. Ownership  
     
  (a) Amount beneficially owned:  
           
        Venrock Healthcare Capital Partners III, L.P. 355,224  (1)  
        VHCP Co-Investment Holdings III, LLC 355,224  (1)  
        Venrock Healthcare Capital Partners EG, L.P. 355,224  (1)  
        VHCP Management III, LLC 355,224  (1)  
        VHCP Management EG, LLC 355,224  (1)  
        Nimish Shah 355,224  (1)  
        Bong Koh 355,224  (1)  
   
  (b) Percent of class:  
           
        Venrock Healthcare Capital Partners III, L.P. 9.99%  (2)  
        VHCP Co-Investment Holdings III, LLC 9.99%  (2)  
        Venrock Healthcare Capital Partners EG, L.P. 9.99%  (2)  
        VHCP Management III, LLC 9.99%  (2)  
        VHCP Management EG, LLC 9.99%  (2)  
        Nimish Shah 9.99%  (2)  
        Bong Koh 9.99%  (2)  
   
  (c) Number of shares as to which the person has:  
           
    (i) Sole power to vote or to direct the vote:  
             
        Venrock Healthcare Capital Partners III, L.P. 0  
        VHCP Co-Investment Holdings III, LLC 0  
        Venrock Healthcare Capital Partners EG, L.P. 0  
        VHCP Management III, LLC 0  
        VHCP Management EG, LLC 0  
        Nimish Shah 0  
        Bong Koh 0  
   
    (ii) Shared power to vote or to direct the vote:  
             
        Venrock Healthcare Capital Partners III, L.P. 355,224  (1)  
        VHCP Co-Investment Holdings III, LLC 355,224  (1)  
        Venrock Healthcare Capital Partners EG, L.P. 355,224  (1)  
        VHCP Management III, LLC 355,224  (1)  
        VHCP Management EG, LLC 355,224  (1)  
        Nimish Shah 355,224  (1)  
        Bong Koh 355,224  (1)  

 

 

 

 

CUSIP No. 88032L605 Page 11 of 14

 

    (iii) Sole power to dispose or to direct the disposition of:  
         
        Venrock Healthcare Capital Partners III, L.P. 0  
        VHCP Co-Investment Holdings III, LLC 0  
        Venrock Healthcare Capital Partners EG, L.P. 0  
        VHCP Management III, LLC 0  
        VHCP Management EG, LLC 0  
        Nimish Shah 0  
        Bong Koh 0  
   
    (iv) Shared power to dispose or to direct the disposition of:  
         
        Venrock Healthcare Capital Partners III, L.P. 355,224  (1)  
        VHCP Co-Investment Holdings III, LLC 355,224  (1)  
        Venrock Healthcare Capital Partners EG, L.P. 355,224  (1)  
        VHCP Management III, LLC 355,224  (1)  
        VHCP Management EG, LLC 355,224  (1)  
        Nimish Shah 355,224  (1)  
        Bong Koh 355,224  (1)  
   

 

  (1) Consists of (i) 33,146 shares of Common Stock and 23,370 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 3,312 shares of Common Stock and 2,336 shares of Common Stock issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 171,875 shares of Common Stock and 121,185 shares of Common Stock issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of Warrants held by the Reporting Persons as a result of the Beneficial Ownership Blockers.
   
    VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
   
  (2) This percentage is calculated based upon the sum of (i) 3,408,906 shares of the Issuer’s Common Stock outstanding as of August 10, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024; and (ii) 146,891 shares issuable upon the exercise of the Warrants described in Footnote 1 above.

 

Item 5. Ownership of Five Percent or Less of a Class
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
  Not applicable

 

 

 

 

CUSIP No. 88032L605 Page 12 of 14

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
   
  Not applicable
 
Item 8. Identification and Classification of Members of the Group
   
  Not applicable
 
Item 9. Notice of Dissolution of Group
   
  Not applicable
 
Item 10. Certification
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

 

 

 

 

CUSIP No. 88032L605 Page 13 of 14

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: August 19, 2024

 

Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
     
By: VHCP Management III, LLC   By: VHCP Management EG, LLC
Its: General Partner   Its :General Partner
         
By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
  Name: Sherman G. Souther     Name: Sherman G. Souther
  Its: Authorized Signatory     Its: Authorized Signatory

 

VHCP Co-Investment Holdings III, LLC    
     
By: VHCP Management III, LLC    
Its: Manager    
     
By: /s/ Sherman G. Souther    
  Name: Sherman G. Souther    
  Its: Authorized Signatory    

 

VHCP Management III, LLC   VHCP Management EG, LLC
     
By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
  Name: Sherman G. Souther     Name: Sherman G. Souther
  Its: Authorized Signatory     Its: Authorized Signatory

 

Nimish Shah    
     
/s/ Sherman G. Souther    
Sherman G. Souther, Attorney-in-fact    
     
Bong Koh    
     
/s/ Sherman G. Souther    
Sherman G. Souther, Attorney-in-fact    

 

 

 

 

CUSIP No. 88032L605 Page 14 of 14

 

EXHIBITS

 

A: Joint Filing Agreement
 
B: Power of Attorney for Nimish Shah
 
C: Power of Attorney for Bong Koh

 

 

 

 

CUSIP No. 88032L605 Page 1 of 1

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Tenax Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

 

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 19th day of August, 2024.

 

Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
     
By: VHCP Management III, LLC   By: VHCP Management EG, LLC
Its: General Partner   Its :General Partner
         
By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
  Name: Sherman G. Souther     Name: Sherman G. Souther
  Its: Authorized Signatory     Its: Authorized Signatory

 

VHCP Co-Investment Holdings III, LLC    
     
By: VHCP Management III, LLC    
Its: Manager    
     
By: /s/ Sherman G. Souther    
  Name: Sherman G. Souther    
  Its: Authorized Signatory    

 

VHCP Management III, LLC   VHCP Management EG, LLC
     
By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
  Name: Sherman G. Souther     Name: Sherman G. Souther
  Its: Authorized Signatory     Its: Authorized Signatory

 

Nimish Shah    
     
/s/ Sherman G. Souther    
Sherman G. Souther, Attorney-in-fact    
     
Bong Koh    
     
/s/ Sherman G. Souther    
Sherman G. Souther, Attorney-in-fact    

 

 

 

 

 

CUSIP No. 88032L605 Page 1 of 1

 

EXHIBIT B

 

POWER OF ATTORNEY FOR NIMISH SHAH

 

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

 

(i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

 

(ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

 

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of August, 2024.

 

/s/ Nimish Shah  

 

 

 

 

 

CUSIP No. 88032L605 Page 1 of 1

 

EXHIBIT C

 

POWER OF ATTORNEY FOR BONG KOH

 

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

 

(i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

 

(ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

 

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of August, 2024.

 

/s/ Bong Koh  

 

 

 

 

Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Tenax Therapeutics Charts.
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Tenax Therapeutics Charts.